Page 2 - Comera Life Sciences News Today

WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve

Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Free Report) major shareholder David Soane purchased 273,838 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were purchased at an average cost of $0.51 per share, for a total transaction of $139,657.38. Following the transaction, the insider now directly owns 225,648 […]

Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Free Report) major shareholder David Soane bought 273,838 shares of the business’s stock in a transaction on Monday, July 31st. The stock was bought at an average cost of $0.51 per share, for a total transaction of $139,657.38. Following the purchase, the insider now directly owns 225,648 […]

– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to...

We have people taking two or three different injectable drugs every other week.

Having patients give themselves injections, when possible, not only saves clinic time and expense, but also spares the patients a trip to the clinic, of course, and often a copay.

Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Rating) was the recipient of a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 39,200 shares, a decline of 12.3% from the May 15th total of 44,700 shares. Currently, 0.5% of the company’s shares are short […]

Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Rating) saw a significant increase in short interest in May. As of May 15th, there was short interest totalling 44,700 shares, an increase of 5.4% from the April 30th total of 42,400 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily […]

Comera Life Sciences (NASDAQ:CMRA – Get Rating) is one of 995 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Comera Life Sciences to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership. Profitability This table compares […]

- Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company - - Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab),